Commission Implementing Regulation (EU) 2023/2592 of 21 November 2023 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-naphthylacetamide, 1-naphthylacetic acid, 2-phenylphenol (incl. its salts such as sodium salt), 8-hydroxyquinoline, amidosulfuron, bifenox, dicamba, difenoconazole, diflufenican, dimethachlor, esfenvalerate, etofenprox, fenoxaprop-P, fenpropidin, fenpyrazamine, fluazifop P, lenacil, napropamide, nicosulfuron, paraffin oils, paraffin oil, penconazole, picloram, prohexadione, spiroxamine, sulphur, tetraconazole and tri-allate

• CELEX: Implementing Regulation (EU) 2023/2592
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

1.

Part A is amended as follows:

(1)

in the sixth column, expiration of approval, of row 169, Amidosulfuron, the date is replaced by ‘15 August 2025’;

(2)

in the sixth column, expiration of approval, of row 170, Nicosulfuron, the date is replaced by ‘31 March 2027’;

(3)

in the sixth column, expiration of approval, of row 172, Dicamba, the date is replaced by ‘31 March 2027’;

(4)

in the sixth column, expiration of approval, of row 173, Difenoconazole, the date is replaced by ‘15 March 2026’;

(5)

in the sixth column, expiration of approval, of row 176, Lenacil, the date is replaced by ‘15 August 2025’;

(6)

in the sixth column, expiration of approval, of row 178, Picloram, the date is replaced by ‘15 February 2028’;

(7)

in the sixth column, expiration of approval, of row 180, Bifenox, the date is replaced by ‘31 March 2027’;

(8)

in the sixth column, expiration of approval, of row 181, Diflufenican, the date is replaced by ‘15 January 2026’;

(9)

in the sixth column, expiration of approval, of row 182, Fenoxaprop-P, the date is replaced by ‘15 August 2025’;

(10)

in the sixth column, expiration of approval, of row 183, Fenpropidin, the date is replaced by ‘15 May 2027’;

(11)

in the sixth column, expiration of approval, of row 284, Dimethachlor, the date is replaced by ‘15 October 2026’;

(12)

in the sixth column, expiration of approval, of row 285, Etofenprox, the date is replaced by ‘31 March 2027’;

(13)

in the sixth column, expiration of approval, of row 287, Penconazole, the date is replaced by ‘15 October 2026’;

(14)

in the sixth column, expiration of approval, of row 288, Tri-allate, the date is replaced by ‘31 March 2027’;

(15)

in the sixth column, expiration of approval, of row 292, Sulphur, the date is replaced by ‘15 April 2025’;

(16)

in the sixth column, expiration of approval, of row 293, Tetraconazole, the date is replaced by ‘31 March 2027’;

(17)

in the sixth column, expiration of approval, of row 294, Paraffin oils, the date is replaced by ‘31 March 2027’;

(18)

in the sixth column, expiration of approval, of row 295, Paraffin oil, the date is replaced by ‘15 August 2025’;

(19)

in the sixth column, expiration of approval, of row 299, 2-phenylphenol (incl. its salts such as sodium salt), the date is replaced by ‘15 November 2027’;

(20)

in the sixth column, expiration of approval, of row 310, Napropamide, the date is replaced by ‘31 March 2027’.

2.

Part B is amended as follows:

(1)

in the sixth column, expiration of approval, of row 6, Prohexadione, the date is replaced by ‘31 May 2026’;

(2)

in the sixth column, expiration of approval, of row 7, Spiroxamine, the date is replaced by ‘31 May 2026’;

(3)

in the sixth column, expiration of approval, of row 12, 1-naphthylacetamide, the date is replaced by ‘31 May 2026’;

(4)

in the sixth column, expiration of approval, of row 13, 1-naphthylacetic acid, the date is replaced by ‘31 May 2026’;

(5)

in the sixth column, expiration of approval, of row 15, Fluazifop P, the date is replaced by ‘31 May 2026’;

(6)

in the sixth column, expiration of approval, of row 18, 8-hydroxyquinoline, the date is replaced by ‘31 December 2024’;

(7)

in the sixth column, expiration of approval, of row 25, Fenpyrazamine, the date is replaced by ‘31 May 2026’.

3.

In Part E:

in the sixth column, expiration of approval, of row 2, Esfenvalerate, the date is replaced by ‘

31 May 2026

’.